Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Hepatology

• Publication date

  2005-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JHEP.2004.10.028PMID 15664255
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

  2004cited by this paper
• Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?

  2004cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Diagnosis, management, and treatment of hepatitis C

  2004cited by this paper
• Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3

  2004cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

  1999cited by this paper

• Cost-effectiveness of screening for hepatitis C in Canada

  2015cites this paper
• Optimal Management of Hepatitis C Genotype 2 Chronic Infection

  2014cites this paper
• How to optimize HCV therapy in genotype 2 patients

  2013cites this paper
• The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C

  2012cites this paper
• Peginterferon-α-2a (40 kD) Plus Ribavirin

  2012cites this paper
• Fibrosis in Liver as a Predictive Marker for Hepatitis C Virus Therapy

  2010cites this paper
• Serum cytokeratin‐18 fragment level: A noninvasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis

  2010cites this paper
• Comments on AASLD practice guidelines for alcoholic liver disease

  2010cites this paper
• Adjunctive vitamin E treatment in Wilson disease and suggestions for future trials

  2010cites this paper
• Treatment of Chronic Hepatitis C in Children

  2010cites this paper
• Reply: Adjunctive vitamin E treatment in Wilson disease and suggestions for future trials

  2010cites this paper
• Reply: Comments on AASLD practice guidelines for alcoholic liver disease

  2010cites this paper
• Reply: Is oil red‐O staining and digital image analysis the gold standard for quantifying steatosis in the liver?

  2010cites this paper
• Reply: Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: The important role of initial ribavirin doses

  2010cites this paper
• Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy

  2010cites this paper
• Thiazolidinediones as potent inducers of hepatocyte growth factor

  2010cites this paper
• Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: The important role of initial ribavirin doses

  2010cites this paper
• Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels

  2009cites this paper
• The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more?

  2009cites this paper
• Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection

  2009cites this paper
• Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection.

  2008cites this paper
• Hepatitis B and C in children

  2008cites this paper
• Meta‐analysis: the outcome of anti‐viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis

  2008cites this paper
• The spread of HIV in Europe: Hidden epidemics and other barriers to universal access to prevention, treatment and care

  2008cites this paper
• Are HCV genotypes 2 and 3 the same or different?

  2008cites this paper
• HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.

  2007cites this paper
• Lack of Rapid Virological Response Predicts Interferon-α2b/Ribavirin Therapy failure in HCV Genotype 2 Patients: A Single-Centre Study

  2007cites this paper
• Short‐duration therapy for hepatitis C: suitable for all?

  2007cites this paper
• The Role of Peginterferon α-2a (40kD) Plus Ribavirin in the Management of Chronic Hepatitis C Mono-Infection

  2006cites this paper
• Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

  2005cites this paper
• Impaired Response to Interferon-α2B plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection

  2005cites this paper
• Fibrosis in Liver as a Predictive Marker for Hepatitis C Virus Therapy

  year unknowncites this paper